Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2018
Billy Ngasala,Mercy G. Chiduo,Samwel Bushukatale,Bruno P. Mmbando,Twilumba Makene,Erasmus Kamugisha,Maimuna Ahmed,Celine I. Mandara,Filbert Francis,Muhidin K. Mahende,Reginald A. Kavishe,Florida Muro,Deus S. Ishengoma,Renata Mandike,Fabrizio Molteni,Frank Chacky,Chonge Kitojo,George Greer,Dunstan Bishanga,Jasmine Chadewa,Ritha Njau,Marian Warsame,Bilali Kabula,Ssanyu S. Nyinondi,Erik Reaves,Ally Mohamed
DOI: https://doi.org/10.1186/s12936-024-04926-x
2024-04-08
Malaria Journal
Abstract:The use of artemisinin-based combination therapy (ACT) is recommended by the World Health Organization for the treatment of uncomplicated falciparum malaria. Artemether-lumefantrine (AL) is the most widely adopted first-line ACT for uncomplicated malaria in sub-Saharan Africa (SSA), including mainland Tanzania, where it was introduced in December 2006. The WHO recommends regular assessment to monitor the efficacy of the first-line treatment specifically considering that artemisinin partial resistance was reported in Greater Mekong sub-region and has been confirmed in East Africa (Rwanda and Uganda). The main aim of this study was to assess the efficacy and safety of AL for the treatment of uncomplicated falciparum malaria in mainland Tanzania.
infectious diseases,tropical medicine,parasitology